Why do you need to know about EASD and it’s activity? EASD annual conference in Munich, Sep 2016

1. Why do you need to know about EASD and it’s activity? EASD annual conference in Munich, Sep 2016

Патракеева Евгения Михайловна
[email protected]

2. Правила

• Вопросы – сразу
• Активное участие приветствуется

3.

Who or what is “EASD”?
EASD is one of the largest networks for diabetologists worldwide with the mission to
promote excellence in diabetes care through research and education.
Aims are to encourage and support research in the field of diabetes,
the rapid diffusion of acquired knowledge and to facilitate its application.

4.

EASD Annual Meeting Attendance 2000 - 2016
24 000
22 000
20 000
18,365
16,577 17,301
18 000
17 895
17 501
14,656
16 000
14 000
10,662
12 000
10 000
17,462 18 127
12,258
13,098 12,681
15 575
15 318
10,069
7,425
8 000
6 000
4 000
2 000
2016
Munich
2015
Stockholm
2014
Vienna
2013
Barcelona
2012
Berlin
2011
Lisbon
2010
Stockholm
2009
Vienna
2008
Rome
2007
Amsterdam
2006
Copenhagen
2005
Athens
2004
Munich
2002
Budapest
2001
Glasgow
2000
Jerusalem
-

5.

EASD Annual Meeting Abstracts Submitted and Accepted
3000
2 498
2 313
2500
2 307
2 165
2 080
2 063
2 159
2 321
2 264
2 145
2 069
1 927
1 904
2000
1.402
1500
1.360
1.250
1.261
1.367
1.352
1.294
1.360
1.332
1.209
1.270
1.195
1167
1000
500
2016
Munich
2015
Stockholm
2014
Vienna
2013
Barcelona
2012
Berlin
2011
Lisbon
2010
Stockholm
2009
Vienna
2008
Rome
2007
Amsterdam
2006
Copenhagen
2005
Athens
2004
Munich
0

6.

Why you should be a member of EASD
EASD unites knowledge from all over the world
Annual Meeting with over 15,000 participants
Journal “Diabetologia” is one of the leading publications in the field
EASD Foundation offers support in all areas of diabetes research
Courses and workshops for education and networking
Recognising of scientific excellence:
the Albert Renold Prize, the Camillo Golgi Prize, the Claude Bernard Prize,
the Minkowski Prize and the EASD-Novo Nordisk Foundation Diabetes Prize for Excellence
• EASD Study groups
EASD is the home of diabetes research in Europe

7.

EASD Study Groups
Artificial Insulin Delivery, Pancreas and Islet Transplantation Study Group (AIDPIT)
Diabetes and Cancer Study Group
Diabetes Education Study Group (DESG)
Diabetes Pregnancy Study Group (DPSG)
Non-alcoholic fatty liver disease (NAFLD)
Diabetes Neuropathy Study Group (NEURODIAB)
Eye Complication Study Group (EASDec)
European Diabetic Nephropathy Study Group (EDNSG)
Incretin Study Group
Islet Study Group
European Diabetes Epidemiology Group (EDEG)
Diabetes and Nutrition Study Group (DNSG)
Psychosocial Aspects of Diabetes Study Group (PSAD)
Diabetic Foot Study Group (DFSG)
Study Group on Metabolic Imaging
Study Group on Primary Care Research in Diabetology (PCDE)
Study Group on Genetics of Diabetes (SGGD)
Diabetes and Cardiovascular Disease Study Group
Exercise and Physical Activity Study Group (ExPAS)
Reactive Metabolites (RMSG)

8.

EASD Postgraduate Courses offer hands-on training
• We strive to cover as many topics as possible
• We use real patients and show real techniques for treatment and
care
• We work with scientists and medical professionals, politics never
plays a role, we are a non-governmental organisation
• We are encouraging young professionals to enter the field of
diabetes
• We are developing the future of diabetes, diabetes research and
diabetes care

9.

10. Results from the delegate survey

Which of the following titles describes your current professional activity best?
Academic/Research
31%
Corporate/Industry
27%
Hospital
25%
General Practicioner
13%
Private Practice
12%
Other
2%
0%
5%
Relative to 1.695 answers, multiple answers possible
10%
15%
20%
25%
30%
35%

11. Results from the delegate survey

Why do you attend the EASD Congress?
Education
66%
Networking
38%
New therapies / diagnostics
37%
General meetings
20%
CME certificate
7%
0%
10%
Relative to 1.712 answers, multiple answers possible
20%
30%
40%
50%
60%
70%

12. Results from the delegate survey

Which session formats are most interesting for you?
Oral presentations
70%
Interactive sessions
36%
Industry Symposia
29%
Posters
28%
Hands-on Sessions/Workshops
20%
0%
10%
Relative to 1.607 answers, multiple answers possible
20%
30%
40%
50%
60%
70%
80%

13. Results from the delegate survey

Will you attend next years EASD Annual Meeting?
100%
92%
90%
80%
70%
60%
50%
40%
30%
20%
8%
10%
0%
Yes
Relative to 1.463 answers
No

14. Abstract Review Process

15. EASD Virtual Meeting Global reach

16. Among the highlights this year:

• SUSTAIN-6: Positive CV outcomes with investigational GLP-1 agonist
semaglutide
• Libre Flash Glucose Monitoring System triples rate of self-monitoring
• Perinatal death increased at full term with gestational diabetes
• Startling results refute the notion that type 1 diabetes is a "juvenile"
condition
• "One-Stop Shop" for diabetic neuropathy and retinopathy screening
• Promising first data on GLP-1 agonist/SGLT2 inhibitor combo
• More LEADER: Liraglutide delays progression of renal events

17. https://www.easdvirtualmeeting.org

18. Another Positive CV Outcomes Trial for Diabetes Drug: SUSTAIN-6

• A second glucagon like-peptide 1 (GLP-1) agonist has shown positive results
in a major cardiovascular-outcomes trial in type 2 diabetes patients at high
risk of cardiovascular disease.
• In the SUSTAIN-6 trial, patients treated with one of two doses of the
investigational agent semaglutide (Novo Nordisk), administered weekly, had
a significant 26% lower risk of the primary composite outcome of first
occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke
over 2 years compared with those on placebo.
• Semaglutide also led to significant and sustained reductions in HbA1c
levels.

19. The main results of the 3200-patient trial conducted in 22 countries were simultaneously published online in the New England

Journal of Medicine

20. 'Flash' Glucose Monitoring

21. Пациент Е., 4 года, СД 6 мес. HbA1c 7,8%

22. Использование уровня интерстициальной глюкозы

Rebrin, Kerstin, Garry M. Steil et al.,
Am. J. Physiol. 277 (Endocrinol. Metab. 40): E561–E571, 1999

23.

24.

25.

26. Libre 'Flash' Glucose Monitoring System Cuts Hypoglycemia

• Use of the Freestyle Libre Flash Glucose Monitoring System (Abbott Diabetes
Care) significantly reduces hypoglycemia without raising HbA1c levels in insulintreated diabetes patients, compared with self-monitoring of blood glucose using
finger sticks.
• "When the patients started using the Libre device, they instantly tripled their rate
of self-monitoring, and this resulted in a marked reduction in time and events
spent in hypoglycemia, time spent in hyperglycemia, an increase in time spent in
optimum range, less glucose variability, and improvements in quality-of-life
measurements,” - Jan Bolinder, Karolinska Institute, Stockholm, Sweden.
• The Libre system comprises a small round glucose sensor worn for up to 14 days
on the back of the upper arm and a scanner device that the patient waves over
the sensor to get a reading of glucose concentrations in the interstitial fluid.
• The scans display both historical and current glucose trends. The Libre system is
now available in 28 countries, with almost 200,000 users globally.

27. Gestational Diabetes: Baby Death Increased at Full Term

• A large French cohort study found a 30% increased risk of perinatal death in
mothers with gestational diabetes who gave birth after 37 weeks, compared
with the risk in nondiabetic mothers.
• This higher risk of the baby dying was the same regardless of whether the woman
was treated with insulin for the gestational diabetes or not.
• However, it was still lower than the risk of perinatal death in mothers with either
type 1 diabetes or type 2 diabetes
• "This increase in perinatal death, particularly in women with untreated
gestational diabetes that we see here, is new. It is often thought that those with
untreated gestational diabetes are less severe and might have lower risk of poor
perinatal outcome”

28. Half of All Type 1 Diabetes Develops After 30 Years of Age

• Onset of type 1 diabetes is just as likely to occur in people older than age 30 as in
those younger
• Obtained using genetic data from the UK Biobank, the startling results refute the
long-held belief that type 1 diabetes is primarily a "juvenile" condition.
• Clinically, the findings are particularly relevant for primary care, where people
who develop autoimmune-mediated diabetes in adulthood are often
misdiagnosed as having type 2 and prescribed metformin instead of insulin.
• "I think it's an eye-opener and obviously has implications for how we diagnose
and manage people and also the education people receive. We very much focus
on childhood and adolescence and perhaps people diagnosed later don't get the
same education”

29. 'One-Stop Shop' for Diabetic Neuropathy Along With Eye Screening

• Assessing patients for diabetic neuropathy while they are having their eyes
examined may be a quick and convenient way of identifying early those who are
at risk of nerve damage.
• Anyone pinpointed could be referred to a special clinic for aggressive risk-factor
management
• "one-stop shop” (Sheffield), whereby diabetes patients coming for retinopathy
screening also have their feet assessed using two new state-of-the-art point-ofcare devices. These are the DPNCheck (NeuroMetrix) — a handheld device that
takes 3 minutes to provide a reading and assesses large-fiber nerve-conduction
velocity and amplitude — and Sudoscan (Impeto Medical), a device that assesses
small nerve fibers, also in about 3 minutes

30.

31. Insulin Users Can Be Safe Pilots (When Following a Protocol)

• Insulin-treated diabetics can be safe air pilots (data from the United Kingdom)
• In 2012, the UK became only the second country in the world (after Canada) to issue
class 1 medical certificates for commercial pilot licenses (CPLs) to people with diabetes
who use insulin (or sulfonylureas/glinides) and who are deemed low risk and follow a set
protocol for glucose monitoring and adjustments.
• About 70 people have been granted such CPLs thus far, and data for 26 of those
individuals were presented by Dr Julia Hine, United Kingdom.
• Over an average follow-up of nearly 2 years, more than 95% of glucose readings were in
the designated "safe" range of 5 to 15 mmol/l (90–270 mg/dL), and no episodes of pilot
medical incapacitation due to low or high blood sugar were reported.
• Key to the program's success is a comprehensive protocol developed by a panel of
medical and aviation experts governing the medical certification of insulin-treated pilots
and based on available literature regarding hypoglycemia risks and experience from
various transport modalities.

32. First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes

• Combining exenatide (Bydureon, AstraZeneca) with dapagliflozin
(Farxiga/Forxiga, AstraZeneca) improved glycemic measures and CV risk
factors more so than each drug alone in patients with type 2 diabetes
inadequately controlled on metformin monotherapy in the DURATION-8
trial.
• The study provides the first evidence of efficacy of coadministration of a
combination of a glucagonlike-peptide 1 (GLP-1) receptor agonist
(exenatide) and a sodium glucose cotransporter 2 (SGLT2) inhibitor
(dapagliflozin)
• The dual treatment regimen was well tolerated, with the expected safety
profile for this combination.

33. Aspirin Overuse May Exceed Underuse in Diabetes

• Aspirin has been overused more often than it has been underused as
primary prevention for cardiovascular disease in patients with diabetes,
according to a new analysis of electronic health record data from a large
primary-care setting.
• The data also reveal that underuse of aspirin for primary prevention has
been more of a problem than overuse in people with reversible CV risk
factors who don't have diabetes.

34. More LEADER: Liraglutide Delays Progression of Renal Events

• The glucagonlike-peptide 1 (GLP-1) agonist liraglutide (Victoza, Novo
Nordisk) delays progression of renal events — in particular, new-onset
persistent macroalbuminuria — in patients with type 2 diabetes, according
to the latest data from the LEADER trial.
• "On top of standard therapy, this GLP-1 agonist [liraglutide] reduced
microvascular outcomes, particularly renal ones” - Dr Mann. He
emphasized that the main driver for the microvascular outcomes was new
and persistent macroalbuminuria, with a risk reduction of 26% seen with
liraglutide compared with placebo (both on top of standard therapy).

35. Global Study Examines Depression With Diabetes

• New research on a global scale shows high rates of depressive disorder
(10%) in patients with type 2 diabetes, but with wide variations between
countries.
• Depression affected almost 30% of type 2 diabetes patients assessed in
Bangladesh, with Mexico, Russia, and Poland also scoring highly, according
to early findings from the International Prevalence and Treatment Study
(INTERPRET-DD)
• The study is following 3000 patients in 15 countries in terms of a recorded
diagnosis of depression and prescribed medication or therapy and

36. EASD.Live

twitter - @EASDnews, fb - @EASD

37. https://www.easdvirtualmeeting.org

38. @diabet.connect

• Около 8000 человек
• Ежедневные обновления страниц
• Авторы – врачи, психолог

39.

• [email protected]
• Twitter @drzhenya
• ИГ @ta_esche_zhenya
• fb, vk Evgeniya Patrakeeva